Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes

Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.